cilostazol has been researched along with Atherogenesis in 33 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the efficacy and safety of cilostazol for atherosclerosis." | 9.22 | Efficacy and Safety of Cilostazol for Atherosclerosis: A Meta-analysis of Randomized Controlled Trials. ( Huang, T; Wan, H; Wu, Q; Wu, T; Yang, P; Zhang, H, 2022) |
| "To compare prevention by cilostazol and aspirin of progression of atherosclerosis, we conducted a prospective, randomized, open, blinded end point study in 4 East Asian countries." | 9.14 | The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. ( Katakami, N; Kawamori, R; Kim, YS; Yamasaki, Y, 2010) |
| "To evaluate the effects of cilostazol, an antiplatelet and vasodilation agent, on the retinal function of patients with non-proliferative diabetic retinopathy (NPDR) using a full-field electroretinogram (ffERG)." | 7.83 | The effect of cilostazol on electrophysiologic changes in non-proliferative diabetic retinopathy patients. ( Kim, HD; Kim, YK; Lee, SH; Oh, JR; Ohn, YH, 2016) |
| "The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits." | 7.81 | Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits. ( Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N, 2015) |
| "Patients with type 2 diabetes and arteriosclerosis obliterans from the Eastern Asian countries were registered online and randomly assigned either to the aspirin group (81-100 mg/day) or the cilostazol group (100-200 mg/day) in this international, 2-year, prospective follow-up interventional study." | 6.72 | Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study). ( Kawamori, R; Kim, YS; Yamasaki, Y, 2006) |
| "Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication." | 6.47 | Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? ( Corrado, E; Mikhailidis, DP; Patti, AM; Rini, GB; Rizzo, M, 2011) |
| "The burden of atherosclerosis is particularly high in western countries in terms of mortality and disability." | 6.46 | Cilostazol in the management of atherosclerosis. ( Di Legge, S; Rotondo, F; Sallustio, F; Stanzione, P, 2010) |
| "To investigate the efficacy and safety of cilostazol for atherosclerosis." | 5.22 | Efficacy and Safety of Cilostazol for Atherosclerosis: A Meta-analysis of Randomized Controlled Trials. ( Huang, T; Wan, H; Wu, Q; Wu, T; Yang, P; Zhang, H, 2022) |
| "To compare prevention by cilostazol and aspirin of progression of atherosclerosis, we conducted a prospective, randomized, open, blinded end point study in 4 East Asian countries." | 5.14 | The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. ( Katakami, N; Kawamori, R; Kim, YS; Yamasaki, Y, 2010) |
| "Patients on cilostazol were divided into 4 groups according to arterial occlusive disease etiology: (1) atherosclerosis, (2) diabetic angiopathy, (3) embolism/thrombosis, and (4) Buerger disease." | 4.31 | Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol? ( Arslan, K; Can Depboylu, B; Funda Tetik, M; Harmandar, B; Ilhan, G; Istar, H; Yazman, S, 2023) |
| "To evaluate the effects of cilostazol, an antiplatelet and vasodilation agent, on the retinal function of patients with non-proliferative diabetic retinopathy (NPDR) using a full-field electroretinogram (ffERG)." | 3.83 | The effect of cilostazol on electrophysiologic changes in non-proliferative diabetic retinopathy patients. ( Kim, HD; Kim, YK; Lee, SH; Oh, JR; Ohn, YH, 2016) |
| "The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits." | 3.81 | Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits. ( Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N, 2015) |
| "Cilostazol (CILO), a selective inhibitor of phosphodiesterase 3 with potent antithrombotic property, has been shown to have a vasculoprotective effect in atherosclerosis animal models due to its potential anti-inflammatory and antioxidant actions." | 3.76 | Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats. ( Hirata, Y; Hirono, Y; Sakurada, M; Sekizawa, N; Suzuki, N; Yoshimoto, T, 2010) |
| "To investigate whether cilostazol (CAS 73963-72-1), a selective phosphodiesterase 3 inhibitor, reduces the progression of atherogenic diet-induced atherosclerosis, cilostazol was orally administered twice a day for 4 weeks to male apolipoprotein-E knockout (ApoE KO) mice." | 3.74 | Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice. ( Hashimoto, A; Hirose, Y; Imaizumi, T; Ito, H; Miyakoda, G; Mori, T; Okutsu, R; Takase, H, 2007) |
| "Cilostazol, an antiplatelet drug, and probucol, a cholesterol-lowering drug, are reported to ameliorate atherosclerosis in animal models." | 3.74 | Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet. ( Kotosai, K; Mitani, K; Miyakoda, G; Nozako, M; Yabuuchi, Y; Yoshikawa, T, 2008) |
| "Cilostazol treatment was associated with significantly lowered IMT in T2D patients compared to aspirin, independent of conventional cardiovascular risk factors." | 2.90 | Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness. ( Chun, M; Hong, S; Kang, J; Kim, D; Lee, K; Little, BB; Nam, M; Paik, S; Park, Y; Woo, J, 2019) |
| "Changes in atherosclerosis are more dynamic in patients with symptomatic ICAS, and the predictors of symptomatic and asymptomatic ICAS differ." | 2.79 | Predictors of symptomatic and asymptomatic intracranial atherosclerosis: what is different and why? ( Cho, YJ; Hong, KS; Kang, DW; Kim, BJ; Kim, JS; Koo, JS; Kwon, SU; Lee, JH; Lee, SH; Park, JM, 2014) |
| "Patients with type 2 diabetes and arteriosclerosis obliterans from the Eastern Asian countries were registered online and randomly assigned either to the aspirin group (81-100 mg/day) or the cilostazol group (100-200 mg/day) in this international, 2-year, prospective follow-up interventional study." | 2.72 | Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study). ( Kawamori, R; Kim, YS; Yamasaki, Y, 2006) |
| "Cilostazol is a selective inhibitor of phosphodiesterase III with anti-platelet-aggregatory and vasodilating properties." | 2.71 | Effects of cilostazol on lipid and fatty acid metabolism. ( Hamazaki, T; Nakamura, N; Okumura, K; Osawa, H; Yamabe, H, 2005) |
| "Cilostazol is a reversible, selective inhibitor of PDE3A able to significantly improve walking distance in patients with intermittent claudication." | 2.47 | Cilostazol and atherogenic dyslipidemia: a clinically relevant effect? ( Corrado, E; Mikhailidis, DP; Patti, AM; Rini, GB; Rizzo, M, 2011) |
| "The burden of atherosclerosis is particularly high in western countries in terms of mortality and disability." | 2.46 | Cilostazol in the management of atherosclerosis. ( Di Legge, S; Rotondo, F; Sallustio, F; Stanzione, P, 2010) |
| "Metallothionein (MT) is a cysteine-rich low molecular weight protein and thought to function in the detoxification of heavy metals and reactive oxygen species." | 1.35 | [Cilostazol induces metallothionein expression in vascular cells]. ( Fujiwara, Y; Kaji, T; Kitagawa, T; Satoh, M; Shinkai, Y, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (30.30) | 29.6817 |
| 2010's | 21 (63.64) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Wan, H | 1 |
| Huang, T | 1 |
| Yang, P | 1 |
| Wu, T | 1 |
| Zhang, H | 1 |
| Wu, Q | 1 |
| Can Depboylu, B | 1 |
| Yazman, S | 1 |
| Harmandar, B | 1 |
| Funda Tetik, M | 1 |
| Istar, H | 1 |
| Arslan, K | 1 |
| Ilhan, G | 1 |
| Rychter, M | 1 |
| Baranowska-Korczyc, A | 1 |
| Milanowski, B | 1 |
| Jarek, M | 1 |
| Maciejewska, BM | 1 |
| Coy, EL | 1 |
| Lulek, J | 1 |
| Umebayashi, R | 1 |
| Uchida, HA | 1 |
| Kakio, Y | 1 |
| Subramanian, V | 1 |
| Daugherty, A | 1 |
| Wada, J | 1 |
| Park, KY | 1 |
| Heo, TH | 1 |
| Hong, S | 1 |
| Nam, M | 1 |
| Little, BB | 1 |
| Paik, S | 1 |
| Lee, K | 1 |
| Woo, J | 1 |
| Kim, D | 1 |
| Kang, J | 1 |
| Chun, M | 1 |
| Park, Y | 1 |
| Chen, Y | 3 |
| Zhao, S | 3 |
| Huang, B | 1 |
| Wang, Y | 3 |
| Li, Y | 3 |
| Waqar, AB | 1 |
| Liu, R | 1 |
| Bai, L | 3 |
| Fan, J | 3 |
| Liu, E | 3 |
| Kim, BJ | 1 |
| Hong, KS | 1 |
| Cho, YJ | 1 |
| Lee, JH | 1 |
| Koo, JS | 1 |
| Park, JM | 1 |
| Kang, DW | 1 |
| Kim, JS | 1 |
| Lee, SH | 2 |
| Kwon, SU | 1 |
| Lin, Y | 2 |
| Guan, H | 2 |
| Zhu, N | 2 |
| Gao, S | 2 |
| Sun, L | 1 |
| Kim, HD | 1 |
| Kim, YK | 1 |
| Oh, JR | 1 |
| Ohn, YH | 1 |
| Gomez, CR | 1 |
| Qureshi, AI | 1 |
| Fujiwara, Y | 1 |
| Kitagawa, T | 1 |
| Shinkai, Y | 1 |
| Kaji, T | 1 |
| Satoh, M | 1 |
| Sakurada, M | 1 |
| Yoshimoto, T | 1 |
| Sekizawa, N | 1 |
| Hirono, Y | 1 |
| Suzuki, N | 1 |
| Hirata, Y | 1 |
| Sallustio, F | 1 |
| Rotondo, F | 1 |
| Di Legge, S | 1 |
| Stanzione, P | 1 |
| Ota, H | 1 |
| Eto, M | 1 |
| Ogawa, S | 1 |
| Iijima, K | 1 |
| Akishita, M | 1 |
| Ouchi, Y | 1 |
| Katakami, N | 1 |
| Kim, YS | 2 |
| Kawamori, R | 2 |
| Yamasaki, Y | 2 |
| Rizzo, M | 1 |
| Corrado, E | 1 |
| Patti, AM | 1 |
| Rini, GB | 1 |
| Mikhailidis, DP | 1 |
| Takeda, M | 1 |
| Yamashita, T | 1 |
| Shinohara, M | 1 |
| Sasaki, N | 1 |
| Tawa, H | 1 |
| Nakajima, K | 1 |
| Momose, A | 1 |
| Hirata, K | 1 |
| Chuang, SY | 2 |
| Yang, SH | 2 |
| Pang, JH | 2 |
| Chen, TY | 1 |
| Jung, IH | 1 |
| Lee, YH | 1 |
| Yoo, JY | 1 |
| Jeong, SJ | 1 |
| Sonn, SK | 1 |
| Park, JG | 1 |
| Ryu, KH | 1 |
| Lee, BY | 1 |
| Han, HY | 1 |
| Lee, SY | 1 |
| Kim, DY | 1 |
| Lee, H | 1 |
| Oh, GT | 1 |
| Garimella, PS | 1 |
| Hart, PD | 1 |
| O'Hare, A | 1 |
| DeLoach, S | 1 |
| Herzog, CA | 1 |
| Hirsch, AT | 1 |
| Bertelli, L | 1 |
| Amato, A | 1 |
| Sangiorgi, GM | 1 |
| Nakamura, N | 1 |
| Osawa, H | 1 |
| Yamabe, H | 1 |
| Okumura, K | 1 |
| Hamazaki, T | 1 |
| Liao, JK | 1 |
| da Rosa, MP | 1 |
| Baroni, GV | 1 |
| Portal, VL | 1 |
| Meadows, TA | 1 |
| Bhatt, DL | 1 |
| Takase, H | 1 |
| Hashimoto, A | 1 |
| Okutsu, R | 1 |
| Hirose, Y | 1 |
| Ito, H | 1 |
| Imaizumi, T | 1 |
| Miyakoda, G | 2 |
| Mori, T | 1 |
| Yoshikawa, T | 1 |
| Mitani, K | 1 |
| Kotosai, K | 1 |
| Nozako, M | 1 |
| Yabuuchi, Y | 1 |
| Lipsitz, EC | 1 |
| Kim, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Cilostazol, a Phosphodiesterase 3 Inhibitor, on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes[NCT03248401] | Phase 4 | 50 participants (Actual) | Interventional | 2016-09-26 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study[NCT01291641] | Phase 4 | 342 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for cilostazol and Atherogenesis
| Article | Year |
|---|---|
Efficacy and Safety of Cilostazol for Atherosclerosis: A Meta-analysis of Randomized Controlled Trials.
Topics: Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggre | 2022 |
Cilostazol in the management of atherosclerosis.
Topics: Animals; Atherosclerosis; Cilostazol; Disease Management; Humans; Phosphodiesterase Inhibitors; Plat | 2010 |
SIRT1/eNOS axis as a potential target against vascular senescence, dysfunction and atherosclerosis.
Topics: Aging; Animals; Atherosclerosis; Cilostazol; Homeostasis; Humans; Nitric Oxide Synthase Type III; Ox | 2010 |
Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?
Topics: Atherosclerosis; Cilostazol; Cyclic Nucleotide Phosphodiesterases, Type 3; Diabetes Mellitus, Type 2 | 2011 |
Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care.
Topics: Amputation, Surgical; Ankle Brachial Index; Atherosclerosis; Cilostazol; Diabetic Foot; Exercise The | 2012 |
Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
Topics: Aspirin; Atherosclerosis; Cilostazol; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dipyr | 2007 |
Cilostazol, a phosphodiesterase III inhibitor: future perspectives in atherosclerosis.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Atherosclerosis; Cilostazol; Cyclic Nucleotide Phosphodiesteras | 2006 |
Clinical aspects of platelet inhibitors and thrombus formation.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Cardiovascular Diseases; Cilostazol; Clopidogrel; Dipyrid | 2007 |
5 trials available for cilostazol and Atherogenesis
| Article | Year |
|---|---|
Randomized control trial comparing the effect of cilostazol and aspirin on changes in carotid intima-medial thickness.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Carotid Intima-Media Thickness; Cilostazol | 2019 |
Predictors of symptomatic and asymptomatic intracranial atherosclerosis: what is different and why?
Topics: Aged; Arteries; Atherosclerosis; Cholesterol, HDL; Cilostazol; Constriction, Pathologic; Disease Pro | 2014 |
The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial.
Topics: Aged; Atherosclerosis; Carotid Artery Diseases; Cilostazol; Diabetes Mellitus, Type 2; Female; Human | 2010 |
Effects of cilostazol on lipid and fatty acid metabolism.
Topics: Aged; Atherosclerosis; Cilostazol; Double-Blind Method; Fatty Acids; Female; Humans; Intermittent Cl | 2005 |
Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study).
Topics: Atherosclerosis; Cilostazol; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Internationality; | 2006 |
20 other studies available for cilostazol and Atherogenesis
| Article | Year |
|---|---|
Do Patients With Arterial Occlusive Disease of Different Etiologies Benefit Equally From Cilostazol?
Topics: Atherosclerosis; Cilostazol; Diabetic Angiopathies; Humans; Peripheral Arterial Disease; Quality of | 2023 |
Cilostazol-Loaded Poly(ε-Caprolactone) Electrospun Drug Delivery System for Cardiovascular Applications.
Topics: Atherosclerosis; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cilostazol; Drug Com | 2018 |
Cilostazol Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysms but Not Atherosclerosis in Apolipoprotein E-Deficient Mice.
Topics: Angiotensin II; Animals; Anti-Inflammatory Agents; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Ath | 2018 |
Combination therapy with cilostazol and pravastatin improves antiatherogenic effects in low-density lipoprotein receptor knockout mice.
Topics: Animals; Aorta; Aortic Diseases; Atherosclerosis; Cell Adhesion Molecules; Cholesterol, Dietary; Cil | 2018 |
Probucol and cilostazol exert a combinatorial anti-atherogenic effect in cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Cholesterol, Dietary; Cilostazol; Drug Th | 2013 |
Peripheral artery disease. Heart health for your legs.
Topics: Angioplasty, Balloon; Atherosclerosis; Cilostazol; Diabetes Complications; Exercise; Fibrinolytic Ag | 2014 |
Demonstration of an add-on effect of probucol and cilostazol on the statin-induced anti-atherogenic effects.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cilostazol; Drug Therapy, Combinat | 2014 |
Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Biomarkers; Cilostazol; Drug Therapy, Combination; Hy | 2015 |
The effect of cilostazol on electrophysiologic changes in non-proliferative diabetic retinopathy patients.
Topics: Adult; Aged; Analysis of Variance; Atherosclerosis; Case-Control Studies; Cilostazol; Diabetes Melli | 2016 |
Medical treatment of patients with intracranial atherosclerotic disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb | 2009 |
[Cilostazol induces metallothionein expression in vascular cells].
Topics: Atherosclerosis; Cadmium; Cells, Cultured; Cilostazol; Endothelial Cells; Humans; Metallothionein; M | 2009 |
Vasculoprotective effect of cilostazol in aldosterone-induced hypertensive rats.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Chemokine CCL2; Cilostazol; Disease Mo | 2010 |
Beneficial effect of anti-platelet therapies on atherosclerotic lesion formation assessed by phase-contrast X-ray CT imaging.
Topics: Animals; Aorta; Apolipoproteins E; Atherosclerosis; Body Weight; Brachiocephalic Trunk; Cell Adhesio | 2012 |
Cilostazol reduces MCP-1-induced chemotaxis and adhesion of THP-1 monocytes by inhibiting CCR2 gene expression.
Topics: Atherosclerosis; Cell Adhesion; Chemokine CCL2; Chemotaxis; Cilostazol; Gene Expression; Humans; Mon | 2011 |
Cilostazol inhibits matrix invasion and modulates the gene expressions of MMP-9 and TIMP-1 in PMA-differentiated THP-1 cells.
Topics: Active Transport, Cell Nucleus; AMP-Activated Protein Kinases; Atherosclerosis; Cell Differentiation | 2011 |
Ginkgo biloba extract (GbE) enhances the anti-atherogenic effect of cilostazol by inhibiting ROS generation.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Cilostazol; Cytokines; Disease Models, Animal; Drug Syn | 2012 |
Treatment of superficial and profunda femoral artery bifurcation lesions: still a procedure only for surgeons?
Topics: Aged; Atherosclerosis; Catheters; Chronic Disease; Cilostazol; Coronary Artery Bypass; Coronary Arte | 2012 |
Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice.
Topics: Aging; Animals; Apolipoproteins E; Atherosclerosis; Cholesterol; Cholesterol, HDL; Cilostazol; Lipid | 2007 |
Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoprotein A-I; Atherosclerosis; Cholesterol; Cilostaz | 2008 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie | 2008 |